Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 1(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07428096Phase 1Active Not Recruiting

A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease

Role: lead

NCT06663605Phase 1Completed

Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.

Role: lead

NCT02836470Phase 2Completed

A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

Role: lead

NCT05470387Phase 3Terminated

A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

Role: lead

All 4 trials loaded